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ABSTRACT Probing drug/lipid interactions at themolecular level represents an important challenge in pharmaceutical research
and membrane biophysics. Previous studies showed differences in accumulation and intracellular activity between two ﬂuoro-
quinolones, ciproﬂoxacin andmoxiﬂoxacin, thatmay actually result from their differential susceptibility to efﬂux by the ciproﬂoxacin
transporter. In view of the critical role of lipids for the drug cellular uptake and differences observed for the two closely related
ﬂuoroquinolones, we investigated the interactions of these two antibiotics with lipids, using an array of complementary techniques.
Moxiﬂoxacin induced, to a greater extent than ciproﬂoxacin, an erosion of theDPPCdomains in theDOPCﬂuid phase (atomic force
microscopy) and a shift of the surface pressure-area isotherms of DOPC/DPPC/ﬂuoroquinolone monolayer toward lower area
per molecule (Langmuir studies). These effects are related to a lower propensity of moxiﬂoxacin to be released from lipid to aque-
ous phase (determined by phase transfer studies and conformational analysis) and a marked decrease of all-trans conformation
of acyl-lipid chains of DPPC (determined by ATR-FTIR) without increase of lipid disorder and change in the tilt between the
normal and the germanium surface (also determined by ATR-FTIR). All together, differences of ciproﬂoxacin as compared to
moxiﬂoxacin in their interactions with lipids could explain differences in their cellular accumulation and susceptibility to efﬂux
transporters.
INTRODUCTION
Since their discovery in the early 1960s, the quinolone group of
antibacterials has generated considerable clinical and scientiﬁc
interest including the development of the second-generation
quinolones like ciproﬂoxacin. These wide spectrum drugs are
characterized by the introduction of ﬂuor into position C-6
on the molecule. Progressive modiﬁcations in their chemical
structure have resulted in improved breadth and potency of in
vitro activity and pharmacokinetics (1). The most signiﬁcant
developments have been enhancement of the therapeutic po-
tential of ﬂuoroquinolones thanks to liposomal encapsulation
(2–4) and improved anti-Gram-positive activity of the newer
compounds like moxiﬂoxacin (5).
Due to their ability to accumulate inside phagocytes (1,6–
8), ﬂuoroquinolones are also useful for eliminating faculta-
tive intracellular pathogens that resist phagocytic death. We
recently showed that ﬂuoroquinolones accumulate in mac-
rophages and show activity against a large array of intra-
cellular organisms including Listeria monocytogenes and
Staphylococcus aureus (9). Quite signiﬁcant differences
among closely related derivatives have been observed with
the following ranking in cellular accumulation and intracel-
lular activity: ciproﬂoxacin, levoﬂoxacin, garenoxacin,
moxiﬂoxacin (9). So far, to our knowledge, this has not re-
ceived satisfactory explanation.
Characterization of ﬂuoroquinolones uptake by eukaryotic
cells suggested that both passive diffusion and active trans-
port systems are involved. The transbilayer diffusion of ﬂuo-
roquinolones has been demonstrated (10) and our group
reported that ciproﬂoxacin, but not moxiﬂoxacin, is subject to
constitutive efﬂux in J774 macrophages through the activity
of an MRP-related transporter (11).
Drug/lipid interactions canmodulate not only translocation
of the drug through the natural membranes but also its inter-
action with efﬂux proteins (12,13). In this respect, it is well
known that 1), substrates have to be transported from the lipid
bilayer to the transporter protein before a capture mechanism
of the drug by the inner leaﬂet of the cytoplasmic membrane
(14); and 2), the activity of transporter is critically dependent
on the surrounding lipid bilayer environment (15,16), which
may be modiﬁed by drugs.
In view of the critical role of lipids for the drug cellular
uptake and differences observed for two closely related
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compounds, ciproﬂoxacin and moxiﬂoxacin (Fig. 1), we in-
vestigated the interactions of these two ﬂuoroquinolones with
lipids, using an array of complementary techniques. For both
ciproﬂoxacin and moxiﬂoxacin, atomic force microscopy
(AFM) reveals an erosion of dipalmitoylphosphatidylcholine
(DPPC) domains within dioleoylphosphatidylcholine (DOPC)
ﬂuid phase while Langmuir studies show a condensing effect.
Further molecular studies show that ﬂuoroquinolones can 1),
exchange from lipids to aqueous phases (phase transfer and
molecular modeling studies); 2), decrease the all-trans con-
formation of lipid acyl chain (attenuated total reﬂection Fou-
rier transform Infra-Red (ATR-FTIR)); and 3), increase the
lipid disorder (ATR-FTIR). When the effects of the two ﬂuo-
roquinolones are compared, it clearly appears that moxi-
ﬂoxacin has a higher condensing effect related to a lower
propensity to be released in the aqueous phase from lipid mono-
layer and to a higher ability to decrease the all-trans conformation
of lipid acyl chain without marked effect in lipid-chain ori-
entation. All together, differences of ciproﬂoxacin as com-
pared to moxiﬂoxacin in their interactions with lipids can
be related to differences in their cellular accumulation and
therefore activity against intracellular bacteria.
MATERIAL AND METHODS
Materials
Dioleoylphosphatidylcholine (DOPC) and dipalmitoylphosphatidylcholine
(DPPC) were purchased from Sigma (St. Louis, MO). Ciproﬂoxacin; mi-
crobiological standard, potency 85,5%, MW ¼ 331.34 g/mol and moxi-
ﬂoxacin; microbiological standard, potency 91%, MW ¼ 401.4 g/mol) were
obtained from Bayer Healthcare AG (Leverkusen, Germany). All other re-
agents were from E. Merck (Darmstadt, Germany).
Fluoroquinolone assays
Ciproﬂoxacin assay
Ciproﬂoxacin content was determined by a ﬂuorimetric method (lex, 275
nm; lem, 450 nm, using a model No. LS-30 Fluorescence Spectrophoto-
meter; Perkin-Elmer, Beaconsﬁeld, UK) as described previously (11). Under
these conditions, our assay had a lower detection limit of ;5 ng/ml, a
linearity (r2 $ 0.99) up to 200 ng/ml, and an intraassay reproducibility of
97%.
Moxiﬂoxacin assay
Fluorescent assay based on the same technique as that used for ciproﬂoxacin
but using lex¼ 298 nm and lem¼ 504 nm; lower limit of detection, 5 ng/ml;
linearity up to 450 ng/ml (r2 $ 0.99); intraassay reproducibility, 98%.
Preparation of liposomes (MLVs, SUVs)
Lipid vesicles were prepared as described previously (17). Brieﬂy, appro-
priate lipids were mixed in CHCl3/CH3OH 2:1 (v/v), evaporated under ni-
trogen ﬂow, and desiccated under vacuum for at least 4 h. The dried ﬁlms
were then resuspended at room temperature from the walls of the glass
balloon by vigorous vortexing in aqueous buffer. Lipid in suspension ﬂushed
with nitrogen were kept in a water bath for 1 h at 37C for pure DOPC or
45C for liposomes containing DPPC. This procedure yields multilamellar
vesicles (MLVs). The small unilamellar vesicles (SUVs) consisting of
DOPC/DPPC (1:1 mol) were prepared from MLVs. The preparation, cooled
down by an ice bath, was sonicated to clarity ﬁve times for 2 min each using a
Fisher Bioblock Scientiﬁc 750 W sonicator (Avantec, Illkirch, France) set at
35% of the maximal power, and a 13-mm probe. The SUVs preparation was
then ﬁltered on 0.2mmAcrodisc ﬁlters (AnnArbor,MI) to eliminate titanium
particles. The concentration of lipids, the nature of the buffer, and the lipid/
drug ratio was adjusted for each type of experiment.
AFM imaging
Mica sheets were heated 1 h before fusion at 60C and cleaved to obtain a ﬂat
and uniform surface. The SUV suspension of DOPC/DPPC (1:1) (10 mg
lipids/ml; buffer 10:100:3 mM, pH 7.4), was put into contact with the mica
surface for 45 min at 60C and the sample was slowly cooled back to room
temperature to prevent thermal shock. The excess of SUVs was then elimi-
nated by four-times rinsing with a Tris/NaCl 10:100 mM buffer, pH 7.4. The
sample was installed on the microscope without dewetting. The liquid me-
niscus was completed with the same buffer or solution containing 0.2 mM
ﬂuoroquinolones. All AFM measurements were carried out at room tem-
perature in contact mode using an optical detection system equipped with a
liquid cell (Nanoscope IV; Digital Instruments, Santa Barbara, CA). Topo-
graphic images were taken in the constant-deﬂection mode using oxide-
sharpened microfabricated Si3N4 cantilevers (Park Scientiﬁc Instruments,
Mountain View, CA) with typical curvature radii of 20 nm and spring
constant of 0.01 N/m. Scan rate ranging from 4 to 6 Hz were tested. The
applied force was maintained as low as possible (,1 nN) during the imaging.
All images were ﬂattened.
Partition of ﬂuoroquinolones—phase transfer
assay between aqueous and lipid phases
For the phase transfer assays, 1 ml of the water phase (Tris pH7.4, 10mM),
containing the ﬂuoroquinolone (1 mM), was mixed by vortexing for 30 s, to
1 ml of organic phase (CHCl3), with or without lipids (Egg yolk phospha-
tidylcholine (PC)) from a lipid/drug ratio of from 0.1:1 up to 50:1. Both
phases were decanted overnight at 4C. The ﬂuoroquinolone recovered from
the water, interfacial, and organic phases were quantiﬁed by ﬂuorimetry
(model No. LS30 ﬂuorimeter; Perkin-Elmer).
Interaction between ﬂuoroquinolones and a
model membrane by molecular modeling: the
IMPALA procedure
The ciproﬂoxacin or moxiﬂoxacin molecule was inserted into an implicit
simpliﬁed bilayer using the IMPALA method described previously (18).
This method simulates the insertion of any molecule into a bilayer by adding
energy restraint functions to the usual energy description of molecules. The
lipid bilayer was deﬁned by C(z), which represents an empirical function
FIGURE 1 (A) Structural formula of ciproﬂoxacin (3-quinolinecarboxylic
acid, 1-cyclopropyl-6-ﬂuoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-(9CI)) and
(B) moxiﬂoxacin (3-quinolinecarboxylic acid, 1-cyclopropyl-6-ﬂuoro-1,4-
dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-
4-oxo-(9CI)).
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describing membrane properties. This function is constant in the membrane
plane (x and y axes), but varies along the bilayer thickness (z axis) and, more
speciﬁcally, at the lipid/water interface corresponding to the transition be-
tween lipid acyl chains (no water ¼ hydrophobic core) and the hydrophilic
aqueous environment,
CðzÞ ¼ 1 1
11 eaðzz0Þ
;
where a is a constant equal to 1.99; z0 corresponds to the middle of polar
heads; and z is the position in the membrane.
Two restraints were imposed to simulate the lipid membrane: the bilayer
hydrophobicity (Epho); and the lipid perturbation (Elip).
The hydrophobicity of the membrane is simulated by Epho,
Epho ¼ +
N
i¼1
SðiÞEtrðiÞCðziÞ;
where N is the total number of atoms; S(i) the accessible surface to solvent of
the i atom; Etr(i) its transfer energy per unit of accessible surface area; and
C(zi) the zi position of atom i.
The perturbation of the bilayer by insertion of the molecule was simulated
by the lipid perturbation restraint (Elip),
Elip ¼ alip +
N
i¼1
SðiÞð1 CðziÞÞ;
where alip is an empirical factor ﬁxed at 0.018 kcal mol
1 A˚2.
The environment energy (Eenv) applied on the drug that inserts into the
membrane becomes equal to
Eenv ¼ Epho1Elip:
Restraint plots
Diagrams showing the restraint values versus the angle between the helix
axis and the bilayer normal or versus the penetration of the mass center are
obtained as follows: for each degree (angle) or for each 1/10 A˚ (penetration),
the lowest restraint value obtained during the Monte Carlo simulation is
taken. All the points are then joined to generate a proﬁle of the simulation.
Calculations are performed on an Intel Pentium 4, CPU 3.80 GHz, 4.00
GB of RAM. The calculation software has been developed at the CBMN
(Gembloux, Belgium). Molecular graphs were drawn using WinMGM 1.0
(Ab Initio Technology, Obernai, France) and Sigmaplot 5.0 (SPSS, Chicago,
IL) was used for data analysis.
Surface-pressure isotherms of lipid
monolayer—Langmuir trough experiments
An automatically controlled Langmuir trough (KSV Minitrough, KSV In-
struments, Helsinki, Finland), equipped with a platinumWilhelmy plate was
used to obtain the surface pressure-area (P–A) isotherms of monolayers at
the air/water interface. The temperature was maintained at 256 0.1C by an
external water bath circulation. The volume of the trough was 80 ml. The
cleanliness of the surface was ensured by closing the barriers, followed by
aspiration of the subphase surface, before each experiment. Each experiment
was started when the ﬂuctuation of the surface pressure was ,0.1 mN/m
during the compression cycle. Lipid mixture (DOPC/DPPC (1:1)) and
DOPC/DPPC mixture with ciproﬂoxacin or moxiﬂoxacin at different molar
proportions (1:1:0.1, 1:1:0.4, 1:1:1, and 1:1:2) were spread from a 1 mM
(1:1:0.1, 1:1:0.4, and 1:1:1 molar ratios) or 2 mM (1:1:2) CHCl3/CH3OH
(2:1, v/v) solution on a Tris 10 mM subphase adjusted at pH 7.4. Thirty
minutes were allowed for solvent evaporation from the interface. The air/
water interface was then compressed with two Delrin barriers at a rate of 5.8
A˚2 molecule1 min1. The reproducibility of the area values remained;7%.
The accuracy on surface pressure was within 0.1 mN/m.
Meanmolecular area (A) of the components at the interface was calculated
taking into account the percentage of ﬂuoroquinolone remaining at the in-
terface after 30 min. The following equation was used:
A ¼ ðAtrough3 1016=NÞ ðMW3 1000=CÞ3V3 103:
Atrough ¼ Area of the trough ðcm2Þ;N ¼ Avogadro
number ð6:0223 1023Þ;MW ¼Weighted average of
themolecular weight of the components remaining
at the interface; C ¼Weighted average of the
concentration ðmg=mlÞ of the components remaining
at the interface;V ¼ Sample volume spread at the interface:
Release of ﬂuoroquinolones from lipid
monolayer to aqueous
phase—Langmuir experiments
The determination of the release of ﬂuoroquinolones from lipid monolayer
into the subphase (Tris buffer 10 mM, pH 7.4) was performed as described
previously. In these experiments, mixed solutions of DOPC/DPPC/ﬂuo-
roquinolone at different molar proportions (1:1:0.1, 1:1:0.4, 1:1:1, and 1:1:2)
were spread from a CHCl3/CH3OH (2:1, v/v) solution on the subphase until a
surface pressure of 11.66 0.8 mN/m was reached. Although this pressure is
well below the estimated surface pressure of a biological membrane (31–34
mN/m (19,20)), it allows an accurate determination of the kinetics of the
transfer of ﬂuoroquinolones to the subphase. Immediately after spreading
and every 5 min, two aliquots of 500 ml were taken from the subphase with a
micropipette. Homogenization of the subphase was provided by a gentle
constant stirring. Each experiment was replicated at least three times. The
presence of lipids was detected by phospholipid assay and ﬂuoroquinolones
were assayed by ﬂuorimetry.
Conformation and orientation of
lipids in interaction with
ﬂuoroquinolones—ATR-FTIR spectroscopy
Attenuated total reﬂection Fourier transform infra-red (ATR-FTIR) is par-
ticularly well suited for the study of membranes and to characterize the effect
of drug interacting with lipids on conformation and orientation of acyl chains
of phospholipids (21). This technique is based on internal reﬂection of the
infrared light within an internal reﬂection germanium plate, which creates an
evanescent ﬁeld at the surface of the plate where the lipid bilayer (and
eventually the bound proteins or drugs) resides (22). After deposit of lipids
on the germanium plate, while evaporating, capillary forces ﬂatten the mem-
branes which spontaneously form oriented multilayer arrangements (23).
The internal reﬂection element was a 52 3 20 3 2 mm trapezoidal germa-
nium ATR plate (ACM, Villiers St. Fre´de´ric, France) with an aperture angle
of 45 yielding 25 internal reﬂections.
Infra-red spectra were obtained on a model No. IFS55 FTIR spectro-
photometer (Bruker, Ettlingen, Germany) purged with N2 (as described
previously (24)). Spectra were recorded with 2 cm1 spectral resolution with
a broad-band MCT detector provided by Bruker between 4000 and 800
cm1; 128 scan were averaged for one spectrum. Amodiﬁed continuous ﬂow
ATR setup was equipped with a polarizer that can be oriented parallel or
perpendicular to the incidence plane. Fifteen microliters of the sample con-
taining DPPC with different lipid/antibiotic molar ratios (DPPC/drug ratio:
1:0, 1:0.2, 1:0.5, 1:1, and 1:2) were dried under a stream of nitrogen on one
side of the germanium internal reﬂection element using an incident angle of
45 at 20C. An elevator under computer control made it possible to move the
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whole setup along a vertical axis (built for us by WOW Company, Nannine,
Belgium). The software used for data processingwaswritten underMatLab 6.5
(The MathWorks, Natick, MA). All spectra were corrected for water vapor
contribution and CO2 and ﬁnally apodized at a resolution of 4 cm
1.
To analyze the conformation of lipids, nonpolarized spectra were re-
corded. The hydrocarbon chain in a-position of DPPC in the gel state is in all
trans from the ester group down to the methyl group. This conformation
allows a resonance to occur between the ester group and the CH2 groups of
the chain, giving rise to the so-called gw(CH2) progression between 1200 and
1350 cm1 (peaks at 1200, 1221, 1246, 1266, 1286, 1309, and 1330 cm1).
The proportion of the a-chains in the all-trans conformation was evaluated
from the area of the band at 1200 cm1 relative to the C-H stretching vi-
brations of the CH2 and CH3 at 3000–2800 cm
1.
To get information about the orientation of lipids and chain ordering,
dichroic spectra of DPPC and DPPC in interaction with ciproﬂoxacin or
moxiﬂoxacin were obtained by subtracting the spectrum measured with a
perpendicular polarization of the incident light (A?) from the spectrum of
absorbance measured with a parallel polarization of the incident light (A//).
The angle between the molecular axis and the membrane normal was cal-
culated as reviewed in Goormaghtigh et al. (21) using the STDWAVE
program developed in the laboratory of one of the authors.
RESULTS
AFM imaging of DOPC/DPPC bilayers incubated
with ciproﬂoxacin and moxiﬂoxacin
To gain insight into ciproﬂoxacin- and moxiﬂoxacin-mem-
brane interactions, supported lipid bilayers made of DOPC/
DPPC were prepared by fusion of unilamellar vesicles on
mica. Time-lapse AFM topographic images were recorded in
solution, in the absence and in the presence of ﬂuoroquino-
lones.
In the absence of drug, classical images previously pub-
lished (13) were obtained. They displayed two discrete height
levels reﬂecting phase separation between gel phase DPPC
and liquid-crystalline phase DOPC. The DPPC gel domains
were well deﬁned and homogenous, with a size ranging from
0.15 to 1.5 mm. The height difference between DPPC do-
mains and the ﬂuid DOPC matrix was 1.10 6 0.05 nm.
When bilayers were incubated with either ciproﬂoxacin
(top panels) or moxiﬂoxacin (bottom panels), we observed a
decrease of the size of DPPC domain with time (Fig. 2). The
height differences between gel phase DPPC and ﬂuid phase
DOPC remains constant during the incubation. We note that
for all incubation times the bilayer surface was devoid of
defects, i.e., holes in the upper monolayer or in the bilayer
were never observed. To evaluate the kinetics of the erosion
process, a plot of the average domain areas was represented
as a function of time. Fig. 3 shows that within a few hours, the
area of DPPC domains decreased from 114.1 to 75.6mm2 and
83.3 to 42.3 mm2 for ciproﬂoxacin and moxiﬂoxacin, re-
spectively. Thus, ciproﬂoxacin induced a decrease of the
surface occupied by the DPPC domain of 27%. This erosion
process was more marked with moxiﬂoxacin since it reached
a value of 58%. The kinetic trend was also different for ci-
proﬂoxacin compared to moxiﬂoxacin, as reﬂected by the
linear and the exponential-like processes, respectively. This
suggests that, in contrast with ciproﬂoxacin, different re-
gimes of erosion had to be distinguished with moxiﬂoxacin.
To assess whether such an alteration of DPPC domains could
be due to mechanical perturbation by the scanning tip, we
performed the same measurements on a control bilayer that
was not incubated with drugs. We obtained an area decrease
of 3% indicating that the time-dependent erosion of the
DPPC gel domains is due to the action of the antibiotics
rather than to a simple scanning effect.
Partition of ciproﬂoxacin and moxiﬂoxacin
measured by phase transfer
The differences in behavior of ciproﬂoxacin and moxi-
ﬂoxacin observed by AFM experiments might be related
to their ability to partition between aqueous and hydropho-
bic environments. To this end, we followed the transfer of
the ciproﬂoxacin and moxiﬂoxacin from an aqueous to a li-
pidic phase, using egg yolk phosphatidylcholine dissolved in
chloroform (Fig. 4). Mostly, egg yolk phosphatidylcholine is
a mixture of C16 and C18 saturated alkyl chains at C-1, and
C18 unsaturated alkyl chain at C-2. Its thickness and degree
of hydration, as well as mean acyl-chain area, are well known
(25,26). Egg yolk phosphatidylcholine is commonly used to
mimic lipid membranes and shows close characteristics of
synthetic lipids used in this study. For example, the thickness
of egg yolk phosphatidylcholine bilayer was estimated to be
30 A˚, a close value to the thickness of DPPC (29.3 A˚) and
DOPC (30 A˚; deduced from the thickness of DSPC, which
has the same carbon number in the alkyl chain as DOPC
(26)). In the absence of lipid, more than 40% of ciproﬂoxacin
was detected in the aqueous phase, while only 5% of moxi-
ﬂoxacine was found in these conditions. A huge amount of
this latter was found at the interface. The addition of lipids to
the organic phase, with a lipid/drug molar ratio up to 50:1 did
not change signiﬁcantly the drug phase transfer.
Transfer of ﬂuoroquinolones from lipid
monolayer to aqueous phase
To get more insight on the partition of ﬂuoroquinolones be-
tween lipid and aqueous phases, we investigated the ability of
ﬂuoroquinolones to be released from a lipid monolayer to an
aqueous phase, by using the Langmuir trough technique. The
amount of ﬂuoroquinolone found in the subphase increased
with the initial quantity of ﬂuoroquinolone in the monolayer
(data not shown). For a DOPC/DPPC/ﬂuoroquinolone ratio
1:1:2, a plateau value was reached within 10 min for cipro-
ﬂoxacin and 15 min for moxiﬂoxacin (Fig. 5). At this equi-
librium state, the percentage of ﬂuoroquinolone detected in
the subphase was clearly higher for ciproﬂoxacin (;70%) as
compared to moxiﬂoxacin (at ;40%). In the experimental
conditions used, no lipid was detected by phospholipid assay
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FIGURE 2 AFM height images (20 mm 3 20 mm
(top panels) or 15 mm 3 15 mm (bottom panels),
z-scale: 5 nm) of a mixed DOPC/DOPC (1:1, mol/mol)
bilayer recorded in Tris 10 mM, NaCl 100 mM buffer,
pH 7.4 containing 1 mM of ciproﬂoxacin (top panels)
or moxiﬂoxacin (bottom panels) at increasing incuba-
tion time.
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in the buffer that supports the lipid-ﬂuoroquinolone mono-
layer.
Conformational analysis of the interactions
between ﬂuoroquinolones and lipids
In an attempt to correlate our experimental data with mo-
lecular modeling, the interaction of ciproﬂoxacin and moxi-
ﬂoxacin with a model membrane was calculated using the
IMPALA method. This procedure was used to study the mem-
brane behavior of both molecules when crossing the bilayer
from the hydrophilic environment to the hydrophobic.
Fig. 6 A shows the most stable position of each molecule
into the membrane. Both ﬂuoroquinolones are clearly located
at the hydrophilic-hydrophobic interface. The molecules
were embedded into the membrane, with their mass center
near the phospholipid headgroup/acyl-chain interface (;13
A˚ from the bilayer center), as shown on the plot of the mass
center position versus the restraints (Fig. 6 B). It should be
noted that differences were seen between ciproﬂoxacin and
moxiﬂoxacin. The interaction of moxiﬂoxacin notably ap-
peared more favorable than that of ciproﬂoxacin, since the
restraint value of the most stable position was 1.5 kcal/mol
lower for moxiﬂoxacin as compared to ciproﬂoxacin.
Effect of ﬂuoroquinolones on lipid
monolayer—surface-pressure isotherms
To investigate the ability of ﬂuoroquinolones to modify the
surface pressure versus area isotherms of DOPC/DPPC (1:1)
monolayers, we investigated the effect of increasing amounts
of antibiotics on these isotherms curves.
For the sake of accuracy, we took into account the release
of ﬂuoroquinolones from the lipid to the aqueous phases in
the determination of the quantity of drug remaining in the
monolayer at the air-water interface, on the monolayers iso-
therms. We therefore recalculated the monolayer compres-
sion isotherms using the proportion of ﬂuoroquinolones
remaining in the monolayer after 30 min. Results are illus-
trated in Fig. 7.
The curve corresponding to pure DOPC/DPPC (1:1) is in
perfect agreement with the one already reported (27). As
already evoked by Montero et al. (28), pure ciproﬂoxacin or
moxiﬂoxacin does not form a ﬁlm at the air-water interface.
FIGURE 3 Evolution of the area of the DPPC domain (Fig. 2) with time
for DOPC/DPPC bilayers incubated in Tris 10 mM, NaCl 100 mM buffer,
pH 7.4, containing 1 mM of ciproﬂoxacin (solid squares) or moxiﬂoxacin
(solid circles).
FIGURE 4 Phase transfer of ciproﬂoxacin (1 mM, top panel) and
moxiﬂoxacin (1 mM, bottom panel) in Tris buffer pH 7.4 against increasing
amounts of PC (from 0.1:1 up to a lipid/drug ratio of 50:1) in chloroform.
(Open bars) Drug in aqueous phase. (Hatched bars) Drug at interface
(calculated from the difference between initial drug concentration and
measured drug in aqueous and organic phase). (Solid bars) Drug in organic
phase. Experiments were reproduced at least three times with similar results.
FIGURE 5 Kinetics of the release of ﬂuoroquinolones from the mixed
lipids/ﬂuoroquinolones monolayer to the subphase (10 mM Tris pH 7.4,
25C). Results are expressed as the percentage of ﬂuoroquinolones initially
present in the monolayer. Ciproﬂoxacin, n; and moxiﬂoxacin, d. Molar
proportion of DPPC/DOPC/ﬂuoroquinolones (1:1:2).
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In presence of ﬂuoroquinolones, the isotherms were shifted
toward the small molecular areas. This effect is more pro-
nounced with moxiﬂoxacin (Fig. 7 B) than ciproﬂoxacin
(Fig. 7 A).
In addition, ﬂuoroquinolones also affected the collapse
pressure: 46.0 mN/m for DOPC/DPPC; 45.9 mN/m, 44.8
mN/m, and 37.7 mN/m, for initial proportions of DOPC/
DPPC/moxiﬂoxacin of 1:1:0.4, 1:1:1, and 1:1:2, respec-
tively; and 46.0 mN/m, 40.5 mN/m, and 37.8 mN/m, for
initial proportions of DOPC/DPPC/ciproﬂoxacin of 1:1:0.4,
1:1:1, and 1:1:2, respectively. This disruption of the lipid
monolayer stability at a high compression level is more
pronounced at a high level of ﬂuoroquinolone in the mixed
monolayer.
Effect of ﬂuoroquinolones on
lipid conformation—ATR-FTIR
Because the lower area occupied by lipids in presence of
ﬂuoroquinolones might be partly due to a change in the ori-
entation of lipid at the interface by straightening up their fatty
acid chains, we used ATR-FTIR to investigate the effect of
ciproﬂoxacin and moxiﬂoxacin on conformation and orien-
tation of acyl chain of lipids.
FIGURE 6 Molecular modeling of the interactions between ciproﬂoxa-
cine and moxiﬂoxacine with an implicit membrane. (A) Most favorable
position of the ciproﬂoxacin (left) and moxiﬂoxacin (right) in a lipid bilayer.
(B) Restraints versus the position of the ciproﬂoxacin (up) and moxiﬂoxacin
(down) in the bilayer. Constraints are expressed in kcal/mol and the positions
are expressed in A˚ngstroms.
FIGURE 7 Surface pressure-molecular area isotherms of DOPC/DPPC in
the presence of ciproﬂoxacin (A) and moxiﬂoxacin (B), on a subphase of 10
mM Tris at pH 7.4 and 25C. Mean molecular area were corrected to take
into account the percentage of ﬂuoroquinolone remaining at the interface.
DOPC/DPPC/drug molar ratio were 1:1:0 (continuous line), 1:1:0.4 (dis-
continuous line), 1:1:1 (dotted line), and 1:1:2 (dash-dotted line).
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Nonpolarized ATR-FTIR spectra of supported layers of
DPPC, drug (ciproﬂoxacin or moxiﬂoxacin), and DPPC/drug
at a molar ratio of 1:1 were recorded (Fig. 8, top panel). As
the drug proportion increased, the drug spectrum appeared in
the DPPC/drug mixture spectrum, notably at 1630 cm1.
Interestingly, in DPPC/drug spectra, the DPPC n(C¼O) band
at 1736 cm1 was modiﬁed in terms of frequency and shape,
suggesting a modiﬁcation of the interfacial lipid carbonyl
groups. Analysis of the lipid C-H wagging (nw(CH2)) al-
lowed us to get information on lipid chain conformation and
proportion of the chains in the all-trans conformation (23).
Here the wagging band at 1200 cm1 was selected because it
has little overlap with other lipid or drug absorption. As
shown in Fig. 8, bottom panel, area evolution of DPPC peak
at 1206–1193 cm1 as function of increasing amounts of
ﬂuoroquinolones decreased by up to 60 and 72% for cipro-
ﬂoxacin and moxiﬂoxacin, respectively. These data indicated
a loss of all-trans conformation and the appearance of a kink
somewhere between C-2 and C-6 of the chain.
Effect of ﬂuoroquinolones on
lipid orientation—ATR-FTIR
To get information on molecular orientation in the absence or
in the presence of both ﬂuoroquinolones, we took advantage
from the fact that, in an ordered membrane deposited on the
germanium crystal (oriented multilayers), all the molecules
have the same orientation with respect to a normal to the
germanium plate. Measuring the spectral intensity with two
orientations of the incident-light electric ﬁeld obtained with a
polarizer allowed us to obtain information on several chem-
ical groups of the lipid molecule. The dichroic spectrum of
pure DPPC and DPPC/drug (molar ratio 1:1) mixture were
obtained by subtracting the spectrum recorded with perpen-
dicular-polarized light from that recorded with the parallel-
polarized light using the lipid n(C¼O) band at 1780–1700
cm1 as a reference (Fig. 9) (29). Interestingly the dichroic
spectra of DPPC/drug mixture displayed strong dichroism for
bands assigned to the drug, notably at 1630 and 1465 cm1,
suggesting a well-organized, well-deﬁned orientation of the
drug in the DPPC bilayer. The orientation of the lipid acyl
chain can be estimated from the wagging band (nw(CH2)).
The dipole of this transition is oriented parallel to the all-
trans chain (23). In turn, positive deviations of the dichroism
spectrum demonstrate that the chains are mainly perpendic-
ular to the germanium surface, i.e., perpendicular to the
membrane plane since AFM recording demonstrated that
membranes orient themselves parallel to the germanium
surface, even when natural membranes are used (30). In Fig.
9, bottom panel, we plotted the area evolution of the wagging
peak integrated between 1206 and 1193 cm1 as a function of
the DPPC/drug molar ratio. Both ﬂuoroquinolones induced a
marked and similar decrease of the area when they were
added at low concentration (1:0.2 molar ratio). When the
amounts of ﬂuoroquinolones were increased, the area de-
creased further in presence of ciproﬂoxacin but remained
almost stable for moxiﬂoxacin. This observation was similar
for the four wagging peaks (indicated by arrows; Fig. 9, top
panel) (1275–1261 cm1, 1253–1240 cm1, 1229–1216
cm1, and 1206–1193 cm1).
To quantify the orientation of DPPC all-trans chains, we
measured the dichroic ratio for wagging band at 1200 cm1.
RATR (A///A?) was 6.8 with an isotropic dichroic ratio of 1.33
(calculated from n(C¼O) band at 1755–1750 cm1 (29)). On
the basis of this determination, the angle between the acyl
chains of DPPC and the normal at the germanium surface was
found to be 21. The same calculation was done in the
presence of ﬂuoroquinolones at a lipid/drug ratio of 1:1. The
angle was 27 and 20 in the presence of ciproﬂoxacin and
moxiﬂoxacin, respectively. These data suggested that in
contrast to ciproﬂoxacin, moxiﬂoxacin had no effect on the
FIGURE 8 Fluoroquinolones effect on the conformation of DPPC mono-
layer as revealed by the infrared absorbance spectra. (Top panel) ATR-FTIR
spectra of moxiﬂoxacin (a), ciproﬂoxacin (b), DPPC (c), DPPC/ciproﬂox-
acin (d), and DPPC/moxiﬂoxacin (e). DPPC was used at 50 mg/ml and the
molar ratio of lipid/drug was 1:1. (Bottom panel) Evolution of the peak area
at 1200 cm1 (wagging gw(CH2) band; integrated between 1206 and 1193
cm1) as a function of increasing lipid/drug ratio: 1:0, 1:0,2, 1:0,5, 1:1, and
1:2. Ciproﬂoxacin, n; and moxiﬂoxacin, d.
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orientation of the acyl chains and did not induce additional
disorder.
DISCUSSION
Our previous studies showed differences in accumulation and
intracellular activity between ciproﬂoxacin and moxiﬂoxacin
that may actually result from their differential susceptibility
to efﬂux by the ciproﬂoxacin transporter (1). Moxiﬂoxacin
differs from ciproﬂoxacin by the presence of a C-8 methoxy
group and a bulkier C-7 (octahydropyrrolo (3.4)-pyridinyl
versus piperazinyl for ciproﬂoxacin) substituent (31). As
previously shown (32), these changes resulted in an increase
in hydrophobicity (log D ;0.28(33) for moxiﬂoxacin and
0.79(34) for ciproﬂoxacin). However, these structural
modiﬁcations between moxiﬂoxacin and ciproﬂoxacin may
not account for the differences in the pK values (from 6.25 to
6.09 (33,36), since these differences are below the experi-
mental errors. Interestingly, these compounds were much
weaker acids than aromatic carboxylic acids. The reduced
acidity may be ascribed to the formation of an intramolecular
hydrogen bond between the carboxyl and neighboring keto
groups in the quinoline ring, resulting in stabilization of the
protonated form of the carboxyl group.
The activity of efﬂux pumps in general, and those involved
for ciproﬂoxacin or moxiﬂoxacin cellular accumulation, in
particular, is closely related to the interaction of the drug with
lipids, regardless of the model proposed for their activity (i.e.,
ﬂippase or hydrophobic vacuum cleaner). We therefore
looked at the inﬂuence of the small changes in chemical
structure between moxiﬂoxacin and ciproﬂoxacin on their
interaction with lipids. To address this crucial question, the
interactions between model lipid membranes and the two
ﬂuoroquinolones were probed using a variety of techniques.
Nanoscale investigations by AFM revealed different be-
haviors for ciproﬂoxacin and moxiﬂoxacin. AFM imaging
showed a reduction of the size of the DPPC gel phase do-
mains in presence of ﬂuoroquinolones. The erosion process is
greater for moxiﬂoxacin compared to ciproﬂoxacin, and
follows an exponential-like function-decrease for moxi-
ﬂoxacin and a linear-decrease for ciproﬂoxacin. Considering
both molecules, the difference in their ability to erode the
DPPC gel phase domains might be due to a better insertion of
the moxiﬂoxacin than the ciproﬂoxacin into the ﬂuid matrix,
and amoremarked decrease of the line tension at the boundary
of the DOPC/DPPC phases resulting from a ﬂuidiﬁcation of
the DPPC.
This marked effect of moxiﬂoxacin on lipids as compared
to ciproﬂoxacin was conﬁrmed by conformational analysis.
In accordance with experimental data obtained for cipro-
ﬂoxacin (37) or grepaﬂoxacin (38), the ﬂuoroquinolones are
located at the lipid-water interface, near the ﬁrst carbons of
the acyl chains. Both molecules showed a minimum of en-
ergy when they are at the phospholipids headgroup/acyl-
chains interface, and the interaction energy rose markedly
when the molecule was forced into the hydrophobic domain.
This energy increase was less marked for moxiﬂoxacin as
compared to ciproﬂoxacin, suggesting a higher afﬁnity of
moxiﬂoxacin for lipid phase.
Taken together, our data suggest that ciproﬂoxacin and
moxiﬂoxacin interact in a very different way with lipids. The
major challenge, however, is to understand the mechanism, at
a molecular level, unraveling the interaction between lipids
and ﬂuoroquinolones and the path of these antibiotic mole-
cules through lipid layers. Previous data reported byMontero
et al. (28) showed a shift of the surface pressure-area iso-
therms of monolayer toward a lower area per molecule in the
presence of ciproﬂoxacin. We extended these data to one
major ﬂuoroquinolone used in clinics, moxiﬂoxacin. To go
further in the mechanism involved, we monitored the amount
FIGURE 9 Fluoroquinolones effect on the orientation of DPPC mono-
layer as revealed by ATR-FTIR dichroic spectra. (Top panel) Polarized ATR-
FTIR spectra of DPPC (a), DPPC/ciproﬂoxacin (b), and DPPC/moxiﬂoxacin
(c). DPPC was used at 50 mg/ml and the molar ratio of lipid/drug was 1:1.
Wagging gw(CH2) bands are indicated by arrows. (Bottom panel) Area evo-
lution of dichroic peak of 1200 cm1 of DPPC in the presence of ﬂuoro-
quinolones. Integration area of dichroic gw(CH2) band (integrated between
1206 and 1193 cm1) was plotted versus DPPC/drug molar ratio as indi-
cated, in the presence of ciproﬂoxacin, n; and moxiﬂoxacin, d.
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of ﬂuoroquinolones in the subphase after the monolayer
compression. In agreement with the hypothesis based on a
dissolving effect in the subphase (39), we did ﬁnd ﬂuoro-
quinolones therein with a higher proportion of ciproﬂoxacin
as compared to moxiﬂoxacin. Taking into account the
amount of ﬂuoroquinolones present inside the monolayer, we
corrected the surface-pressure-area isotherms of the mono-
layer and again observed a shift toward a lower area per
molecule in the presence of ﬂuoroquinolones. This effect was
more marked with moxiﬂoxacin as compared to cipro-
ﬂoxacin. The dissolving effect in the aqueous phase is
therefore probably essential, although not fully sufﬁcient, to
explain the condensing effect of ﬂuoroquinolones.
Thus, we investigated a change in the lipid chain confor-
mation and orientation using ATR-FTIR technique (21,40).
Indeed, the drug-induced area condensation of lipids can
derive from the acyl ordering attained when trans-gauche
isomerization about the carbon-carbon bonds is reduced. The
trans conformation is the most stable and has an estimated
energy barrier of 3.5 kcal/mol to rotate past the eclipsed
conﬁguration to the gauche form. The all-trans conformation
allows the chain to be maximally extended, whereas a gauche
bond alters the direction of the chain inducing a kink in the
chain. Our results clearly indicated that moxiﬂoxacin has a
higher ability than ciproﬂoxacin to markedly decrease the
number of all-trans conformation. The related change in the
packing of the acyl chains might allow moxiﬂoxacin to be
located in the pocket created by the presence of a kink in the
acyl chain. In contrast, with ciproﬂoxacin, the appearance of
a kink from the all-trans chain conformation would be less
marked, suggesting a less important change in lipid packing.
Interestingly, both condensing effects (lower area of mixed
monolayer lipids/ﬂuoroquinolones) have also been described
when cholesterol was added to ﬂuid-phase phosphatidyl-
choline (41–43).
The disorder in the lipid chains revealed by the decrease of
all-trans conformations has also been analyzed in terms of
orientation and tilt between the molecular axis (the mem-
brane normal) and the transition dipole moments. In this
analysis, the ciproﬂoxacin showed an additional cause of
disorder, because it modiﬁes the orientation of the acyl chain
in relation to its higher ability to be released in an aqueous
phase after monolayer compression.
Differences in the charge distribution of the molecule at the
physiological pH could also explain changes for drug
membrane location and bound hydration shell surrounding
the headgroup of membrane lipids, which, in turn, could
partly explain the more condensing effect of moxiﬂoxacin as
compared to ciproﬂoxacin. Moreover, the determinations
were made in aqueous environment, whereas the condensing
effect of moxiﬂoxacin involved the presence of the drug with
a lipidic phase.
All together, we showed that the condensing effect of
ﬂuoroquinolones on lipid layer resulted not only from a
dissolving mechanism but also from an alteration of the in-
tramolecular acyl-chain order in relation to a reduction in
trans-gauche isomerization about the carbon-carbon bonds,
and change in the average molecular tilt of lipid acyl chain of
DPPC. The two ﬂuoroquinolones investigated showed dif-
ference in their effects. Ciproﬂoxacin had a lower ability to
decrease the all-trans conformation of lipid chains than
moxiﬂoxacin but showed a higher capacity to affect the ori-
entation of lipid chains and to disorder the membrane. These
effects might explain its higher ability to be released from the
lipid monolayer to aqueous phase and its lower effect on
surface pressure-area isotherms of monolayers. In contrast,
moxiﬂoxacin has a lower capacity to induce membrane dis-
order and does not change the tilt between the molecular axis
and the transition dipole moment. Moxiﬂoxacin has also a
higher tendency to decrease the number of all-trans confor-
mations with increase of kink, creating a pocket in which
moxiﬂoxacin can be located. This can explain why the
amount of moxiﬂoxacin in the aqueous phase was lower than
that found for ciproﬂoxacin and why the mean molecular area
of lipids/ﬂuoroquinolones monolayers after compression is
signiﬁcantly lower in the presence of moxiﬂoxacin as com-
pared to ciproﬂoxacin.
This model is entirely compatible with the physico-
chemical characteristics of the two ﬂuoroquinolones. It
suggested that small structural differences among ﬂuoroquin-
olones (notably overall molecular hydrophobicity (Papp ¼
0.089 vs. 0.031 for ciproﬂoxacin and moxiﬂoxacin, respec-
tively (45)), bulkiness, and/or the internal dynamics of the C-7
substituent, could be important for drug lipid interactions and
lipid packing. The diazabicyclonyl-ring at position 7 of
moxiﬂoxacin, by aligning the sn-2 chain, probably contributes
to the higher tendency of this antibiotic to induce a decrease of
all-trans conﬁguration as compared to ciproﬂoxacin. This is in
line with data reported with n-alkyl-piperazinyl-ciproﬂoxacin
(39).
In conclusion, we provided a comprehensive picture of the
interaction of the two major ﬂuoroquinolones ciproﬂoxacine
and moxiﬂoxacine with lipids, and elucidate fundamental
issues such as the relationship between lipid chain confor-
mation and orientation with changes in membrane properties
as determined by Langmuir studies and the ability of drugs to
diffuse through membranes. All these parameters might be
related to the activity of membranous proteins. Our work
notably showed that an increase in drug lipophilicity and
addition of a bulky moiety (moxiﬂoxacin versus cipro-
ﬂoxacin) produced marked changes in the packing of lipids.
This was concomitant with a lower release of the more lip-
ophilic drug from lipid monolayer and with a potential in-
efﬁcient activity of efﬂux proteins which could be involved in
a kind of futile cycle resulting in an increase in cellular ac-
cumulation (1). So far, progress in understanding the struc-
ture-function relationships of membranes and understanding
of the lipid-drug interaction appears to be of crucial impor-
tance in understanding the mechanisms involved in cellular
drug accumulation.
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